Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Medical Officer | August 04, 2026 | August 06, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 54,645 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 30,000 · Balance 54,645 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · derivative · entry 9 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F8 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 43,500 | $0.00 Strike: $35.54 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · derivative · entry 8 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,500 Underlying: Common stock · 43,500 shares Expires 2035-03-01 F7 · derivative.exercise_date: This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · derivative · entry 7 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F6 · derivative.expiration_date: The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · nonDerivative · entry 5 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · nonDerivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000013 · wk-form4_1741122508.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 666 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000111 · wk-form4_1720038596.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,749 Underlying: Common stock · 8,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,705 | $43.85 | $162,464.25 |
DisclosureSEC source: 0001439222-24-000111 · wk-form4_1720038596.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,736 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000111 · wk-form4_1720038596.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:25 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000950170-24-079084 · ownership.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2034-06-26 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,349 | $32.57 | $43,936.93 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · nonDerivative · entry 4 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,066 F3 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,293 | $32.57 | $42,113.01 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,415 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · derivative · entry 8 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: Common stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F8 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · derivative · entry 7 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,833 Underlying: Common stock · 3,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F7 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 60,000 | $0.00 Strike: $32.27 | $0.00 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · derivative · entry 6 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common stock · 60,000 shares Expires 2034-03-01 F6 · derivative.exercise_date: This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · derivative · entry 5 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,000 Underlying: Common stock · 17,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · nonDerivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000054 · wk-form4_1709673617.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,587 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 22:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 642 | $25.14 | $16,139.88 |
DisclosureSEC source: 0001439222-24-000030 · wk-form4_1707951190.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,431 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000030 · wk-form4_1707951190.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:53 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000030 · wk-form4_1707951190.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 24, 2024 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,708 | $21.64 | $36,961.12 |
DisclosureSEC source: 0001439222-24-000020 · wk-form4_1706131453.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,911 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000020 · wk-form4_1706131453.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on March 1, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on March 1, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000020 · wk-form4_1706131453.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2024 Filed Jan 9, 2024 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,789 | $22.99 | $41,129.11 |
DisclosureSEC source: 0001439222-24-000004 · wk-form4_1704835314.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,869 F2 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 1, 2021. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000004 · wk-form4_1704835314.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The PSUs were granted on September 1, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The PSUs were granted on September 1, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000004 · wk-form4_1704835314.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 499 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 20:35 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0000950170-23-049704 · ownership.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-09-21 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| July 01, 2023 Filed Jul 6, 2023 20:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 25,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000111 · wk-form4_1688673850.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,124 Underlying: Common stock · 25,124 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,707 | $28.36 | $48,410.52 |
DisclosureSEC source: 0001439222-23-000105 · wk-form4_1688155583.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,159 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000105 · wk-form4_1688155583.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,750 Underlying: Common stock · 5,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000105 · wk-form4_1688155583.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,134 | $25.02 | $28,372.68 |
DisclosureSEC source: 0001439222-23-000047 · wf-form4_167787751050589.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,116 Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000047 · wf-form4_167787751050589.xml · derivative · entry 5 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,667 Underlying: Common stock · 3,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 44,000 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001439222-23-000047 · wf-form4_167787751050589.xml · derivative · entry 4 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common stock · 44,000 shares Expires 2033-03-01 F4 · derivative.exercise_date: This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000047 · wf-form4_167787751050589.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000047 · wf-form4_167787751050589.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 408 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 14, 2023 Filed Feb 14, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 758 | $28.44 | $21,557.52 |
DisclosureSEC source: 0001439222-23-000017 · wf-form4_167640880440163.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,009 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000017 · wf-form4_167640880440163.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,162 Underlying: Common stock · 2,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000017 · wf-form4_167640880440163.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2022 Filed Dec 28, 2022 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,783 | $28.48 | $79,259.84 |
DisclosureSEC source: 0001439222-22-000104 · wf-form4_167226148971361.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,605 Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000104 · wf-form4_167226148971361.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022. F2 · derivative.expiration_date: The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000104 · wf-form4_167226148971361.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2022 Filed Dec 6, 2022 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 248 | $28.83 | $7,149.84 |
DisclosureSEC source: 0001439222-22-000101 · wf-form4_167036124284100.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,013 Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000101 · wf-form4_167036124284100.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000101 · wf-form4_167036124284100.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 660 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 41,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001439222-22-000029 · wf-form4_164634182660786.xml · derivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common stock · 41,000 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000029 · wf-form4_164634182660786.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common stock · 11,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 955 | $29.08 | $27,771.40 |
DisclosureSEC source: 0001439222-22-000021 · wf-form4_164565070684880.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,768 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 3,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000021 · wf-form4_164565070684880.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,272 Underlying: Common stock · 3,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.